Back to today’s briefing

Story perspectives

India's DengiAll Vaccine Aims to Combat Dengue Epidemic

2/27/2026

36 6 Full Breakdown

Summary

Story summary

DengiAll, a dengue vaccine candidate developed by Panacea Biotec in New Delhi, is in final Phase III trials as a potential single-dose vaccine.
The World Health Organization reports nearly half the global population is at risk of dengue.
India has logged over one million dengue cases since 2021.
If approved, DengiAll would be the first licensed dengue vaccine in India, with results expected in late 2026.

1 of 1

Story summary

DengiAll, a dengue vaccine candidate developed by Panacea Biotec in New Delhi, is in final Phase III trials as a potential single-dose vaccine.
The World Health Organization reports nearly half the global population is at risk of dengue.
India has logged over one million dengue cases since 2021.
If approved, DengiAll would be the first licensed dengue vaccine in India, with results expected in late 2026.